Data_Sheet_1_Pan-Cancer Analysis of Genomic and Prognostic Characteristics Associated With Coronavirus Disease 2019 Regulators.ZIP

Background: Cancer patients are alleged to have poor coronavirus disease 2019 (COVID-19) outcomes. However, no systematic or comprehensive analyses of the role and mechanisms of COVID-19 receptor-related regulators in cancer are available. Methods: We comprehensively evaluated the genomic alterations and their clinical relevance of six COVID-19 receptor-related regulators [transmembrane serine protease 2 (TMPRSS2), angiotensinogen (AGT), angiotensin-converting enzyme 1 (ACE1), solute carrier family 6 member 19 (SLC6A19), angiotensin-converting enzyme 2 (ACE2), and angiotensin II receptor type 2 (AGTR2)] across a broad spectrum of solid tumors. RNA-seq data, single nucleotide variation data, copy number variation data, methylation data, and miRNA–mRNA interaction network data from The Cancer Genome Atlas (TCGA) of 33 solid tumors were analyzed. We assessed the sensitivities of drugs targeting COVID-19 receptor-related regulators, using information from the Cancer Therapeutics Response Portal database. Results: We found that there are widespread genetic alterations of COVID-19 regulators and that their expression levels were significantly correlated with the activity of cancer hallmark-related pathways. Moreover, COVID-19 receptor-related regulators may be used as prognostic biomarkers. By mining the genomics of drug sensitivities in cancer databases, we discovered a number of potential drugs that may target COVID-19 receptor-related regulators. Conclusion: This study revealed the genomic alterations and clinical characteristics of COVID-19 receptor-related regulators across 33 cancers, which may clarify the potential mechanism between COVID-19 receptor-related regulators and tumorigenesis and provide a novel approach for cancer treatments.背景：既往研究提示，癌症患者的2019冠状病毒病（coronavirus disease 2019, COVID-19）预后不佳，但目前尚无针对癌症中COVID-19受体相关调控因子的作用与机制开展的系统性、综合性分析。 方法：本研究针对六大类COVID-19受体相关调控因子——跨膜丝氨酸蛋白酶2（transmembrane serine protease 2, TMPRSS2）、血管紧张素原（angiotensinogen, AGT）、血管紧张素转换酶1（angiotensin-converting enzyme 1, ACE1）、溶质载体家族6成员19（solute carrier family 6 member 19, SLC6A19）、血管紧张素转换酶2（angiotensin-converting enzyme 2, ACE2）及血管紧张素Ⅱ受体2型（angiotensin II receptor type 2, AGTR2），在广泛实体瘤中的基因组改变及其临床相关性展开全面评估。我们分析了来自33种实体瘤的癌症基因组图谱（The Cancer Genome Atlas, TCGA）中的RNA测序（RNA-seq）数据、单核苷酸变异数据、拷贝数变异数据、甲基化数据以及miRNA-mRNA相互作用网络数据。同时借助癌症治疗反应门户（Cancer Therapeutics Response Portal）数据库信息，评估了靶向COVID-19受体相关调控因子的药物敏感性。 结果：本研究发现COVID-19调控因子存在广泛的遗传改变，且其表达水平与癌症特征相关通路的活性显著相关。此外，COVID-19受体相关调控因子可作为预后生物标志物。通过挖掘癌症数据库中的药物敏感性基因组学数据，本研究筛选出多个可靶向COVID-19受体相关调控因子的潜在药物。 结论：本研究阐明了33种癌症中COVID-19受体相关调控因子的基因组改变与临床特征，可为解析COVID-19受体相关调控因子与肿瘤发生之间的潜在机制提供依据，并为癌症治疗提供全新策略。